Fondazione IRCCS San Gerardo Dei Tintori, Monza, Italy.
Dipartimento Di Medicina E Chirurgia, Università Degli Studi Milano-Bicocca, Monza, Italy.
J Clin Immunol. 2023 Nov;43(8):2192-2207. doi: 10.1007/s10875-023-01583-8. Epub 2023 Oct 14.
GATA2 deficiency is a rare disorder encompassing a broadly variable phenotype and its clinical picture is continuously evolving. Since it was first described in 2011, up to 500 patients have been reported. Here, we describe a cohort of 31 Italian patients (26 families) with molecular diagnosis of GATA2 deficiency. Patients were recruited contacting all the Italian Association of Pediatric Hematology and Oncology (AIEOP) centers, the Hematology Department in their institution and Italian societies involved in the field of vascular anomalies, otorhinolaryngology, dermatology, infectious and respiratory diseases. Median age at the time of first manifestation, molecular diagnosis and last follow-up visit was 12.5 (age-range, 2-52 years), 18 (age-range, 7-64 years) and 22 years (age-range, 3-64), respectively. Infections (39%), hematological malignancies (23%) and undefined cytopenia (16%) were the most frequent symptoms at the onset of the disease. The majority of patients (55%) underwent hematopoietic stem cell transplantation. During the follow-up rarer manifestations emerged. The clinical penetrance was highly variable, with the coexistence of severely affected pediatric patients and asymptomatic adults in the same pedigree. Two individuals remained asymptomatic at the last follow-up visit. Our study highlights new (pilonidal cyst/sacrococcygeal fistula, cholangiocarcinoma and gastric adenocarcinoma) phenotypes and show that lymphedema may be associated with null/regulatory mutations. Countrywide studies providing long prospective follow-up are essential to unveil the exact burden of rarer manifestations and the natural history in GATA2 deficiency.
GATA2 缺陷是一种罕见的疾病,具有广泛的可变表型,其临床表现不断演变。自 2011 年首次描述以来,已报告了多达 500 例患者。在这里,我们描述了一组 31 名意大利患者(26 个家族)的 GATA2 缺陷分子诊断。通过联系所有意大利儿科血液学和肿瘤学协会(AIEOP)中心、其所在机构的血液科以及涉及血管异常、耳鼻喉科、皮肤科、传染病和呼吸道疾病领域的意大利协会,招募了患者。首次表现、分子诊断和最后一次随访的中位年龄分别为 12.5 岁(年龄范围为 2-52 岁)、18 岁(年龄范围为 7-64 岁)和 22 岁(年龄范围为 3-64 岁)。感染(39%)、血液系统恶性肿瘤(23%)和未定义的血细胞减少症(16%)是疾病发作时最常见的症状。大多数患者(55%)接受了造血干细胞移植。在随访期间,出现了更罕见的表现。临床外显率差异很大,同一家系中既有严重受影响的儿科患者,也有无症状的成人。有两名患者在最后一次随访时仍无症状。我们的研究强调了新的表型(藏毛窦/尾骶骨瘘、胆管癌和胃腺癌),并表明淋巴水肿可能与无效/调节突变有关。全国性的研究提供长期前瞻性随访对于揭示 GATA2 缺陷的罕见表现的确切负担和自然史至关重要。